Diazaspiroheptane Core Modulators for Selective T-Type Calcium Channels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for conditions associated with aberrant T-type calcium channel function, such as psychiatric disorders, pain, tremor, and epilepsy, lack selective modulators that effectively target these channels.
Innovation Solution
Development of diazaspiroheptane core compounds with specific left and right-hand substitutions that modulate T-type calcium channels, providing therapeutic benefits for conditions like major depressive disorder, essential tremor, and epilepsy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for conditions associated with T-type calcium channel function, then treatment coverage is provided, but selective modulation of T-type calcium channels is lacking
Solution Approach 1:
The patent applies local quality by introducing specific substitution patterns at defined positions (X1, X2, X3) on the diazaspiroheptane core structure. Each position has specific chemical group requirements that optimize interaction with T-type calcium channels while maintaining selectivity. This localized structural optimization enables selective modulation without compromising broad treatment coverage for multiple conditions including psychiatric disorders, pain, tremor, and epilepsy.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types (halogens, alkyl groups, aryl groups), their positions, and stereochemical configurations on the diazaspiroheptane core. These parameter variations allow optimization of binding affinity and selectivity for T-type calcium channels across different disease states, achieving both reliable selective modulation and versatile treatment coverage.
2Reliability
If diazaspiroheptane core compounds with specific substitutions are developed, then selective modulation of T-type calcium channels is achieved, but compound structural complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional segments: a core diazaspiroheptane structure and three specific substitution positions (X1, X2, X3). Each segment has defined chemical group options that can be independently selected and optimized. This modular segmentation achieves selective modulation while managing structural complexity through systematic organization of chemical variations.
Solution Approach 2:
The patent employs universality by designing a core diazaspiroheptane structure that serves multiple functions: providing structural stability, enabling selective T-type calcium channel binding, and allowing versatile substitution patterns. The core structure universally supports various substituent types (halogens, alkyl, aryl groups) at defined positions, achieving selective modulation across different disease indications without proportionally increasing complexity.
Data Source
AI summary
Disclosed herein are compounds for treating a condition modulated by calcium channel ion activity and pharmaceutical compositions comprising the compounds, wherein the compounds comprise a diazaspiroheptane core and left- and right-hand substitutions of the diazaspiroheptane core. Also disclosed herein are methods using the compounds to treat a disease or condition relating to aberrant function or activity of a T-type calcium channel.